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RUTHENIUM-106 BRACHYTHERAPY FOR UVEAL MELANOMAS –
PRELIMINARY RESULTS: A SINGLE INSTITUTIONAL EXPERIENCE*
Rodrigo Souza Dias1, Adelmo José Giordani1, Clélia Maria Erwenne2, Helena Regina Comodo
Segreto1, Luiz Fernando Teixeira2, Roberto Araujo Segreto1
OBJECTIVE: To analyze the early response of uveal melanomas in patients treated with ruthenium-106
brachytherapy. MATERIALS AND METHODS: In the period between April 2002 and July 2003, 20 patients
diagnosed with uveal melanoma were submitted to ruthenium-106 brachytherapy. The calculated dose de-
livered at the apex of the tumor ranged between 55 Gy and 100 Gy. Patients with lesions greater than 5 mm
were submitted to transpupillary thermotherapy concomitantly with ophthalmic plaque insertion. RESULTS:
As regards the lesions site, 75% of the lesions were located in the choroid, 15% in the iris, and the remain-
der 10% in the ciliary body. In a median 19-month-follow-up, the progression-free survival for brachytherapy
was 69%, and 87% for associated brachytherapy and transpupillary thermotherapy. A significant tumor height
reduction was observed after treatment. No patient was submitted to enucleation. CONCLUSION: Our pre-
liminary results show that ruthenium-106 brachytherapy is an appropriate method for conservative treat-
ment of patients with uveal melanomas in terms of local management, ocular and visual acuity preservation
with an acceptable complications incidence rate.
Keywords: Uveal melanoma; Ruthenium plaque therapy; Conservative therapy; Brachytherapy.
Braquiterapia com rutênio-106 em melanomas uveais – resultados preliminares: experiência uni-institucio-
nal.
OBJETIVO: Analisar os resultados preliminares da braquiterapia com rutênio-106 em pacientes portadores
de melanomas uveais. MATERIAIS E MÉTODOS: No período de abril de 2002 a julho de 2003, 20 pacientes
com diagnóstico de melanoma uveal foram tratados com braquiterapia com rutênio-106. A dose calculada
no ápice tumoral variou de 55 Gy a 100 Gy. Pacientes com lesões com altura maior que 5 mm foram sub-
metidos a termoterapia transpupilar concomitante à colocação da placa oftálmica. RESULTADOS: Quanto à
localização da lesão, esta se encontrava na coróide em 75% dos casos, na íris em 15% e no corpo ciliar em
10% dos pacientes. Com seguimento mediano de 19 meses, a sobrevida livre de progressão para a braqui-
terapia e para a associação com a termoterapia transpupilar foi de 69% e 87%, respectivamente. Observou-
se redução significante da altura tumoral após o tratamento. Nenhum dos pacientes foi submetido a enuclea-
ção. CONCLUSÃO: Nossos resultados preliminares mostram que a braquiterapia com rutênio-106 é uma opção
adequada para o tratamento conservador de melanomas uveais em termos de controle local, manutenção do
globo ocular e visão útil, com índice aceitável de complicações.
Unitermos: Melanoma uveal; Placa de rutênio; Tratamento conservador; Braquiterapia.
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INTRODUCTION
Although rare, uveal melanoma is the
most common primary intra-ocular malig-
nancy in adults, with an approximate fre-
quency of six cases per million inhabitants
per year in the United States(1,2), seven
cases per million inhabitants per year in the
Western Europe(3). Estimates for Brazil are
not available.
Up to the eighties, the treatment for pa-
tients with uveal melanoma was surgical,
consisting in enucleation, still the mainstay
of therapeutical intervention for extensive
lesions. However, other therapies aiming at
preserving the vision and the ocular globe
have been proposed since 1930(4).
In 1930, Moore utilized radon seeds di-
rectly implanted into the ocular tumor of a
patient(4). In 1960, Stallard initiated the
treatment for these tumors with cobalt-60
episcleral plaques. Since then, other iso-
topes like iodine-125, iridium-192, gold-
198, paladium-103 and ruthenium-106
started being utilized(6–8).
Randomized prospective studies like
those developed by the Collaborative Ocu-
lar Melanoma Study (COMS) since 1986,
showed that the mortality rate of patients
with melanomas between 2.5 mm and 10
mm in elevation was similar when com-
pared with the mortality rate for patients
submitted to iodine-125 brachytherapy and
to enucleation(6). Yet, in 1986, Lommatzsch
reported the utilization of ruthenium-106
beta-radiation for treatment of uveal mela-
nomas with results comparable to those
from other radioisotopes(7). So, ocular
brachytherapy started being used in pa-
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tients with uveal melanomas with up to 10
mm in elevation, allowing results similar to
those from more radical procedures like
enucleation, while preserving the visual
acuity and the ocular globe.
Amongst the radioisotopes most fre-
quently utilized in ocular brachytherapy,
cobalt-60 is a gamma-radiation emitter
with 1.25 MeV energy and 5.2-year half-
life, whose main disadvantages are the
higher radiation exposure of the medical
team and higher radiation dose in adjacent
organs, and iodine-125, a gamma-radiation
emitter with 0.028 MeV energy and a rela-
tively short 59.6-day half-life. As regards
ruthenium-106, this isotope presents as
main characteristic the beta-radiation emis-
sion, allowing higher dose concentration in
the tumor, and lower dose in adjacent ar-
eas. Besides, the medical team involved in
the procedure is submitted to lower expo-
sure to radiation, and organs in risk receive
lower radiation doses, consequently opti-
mizing the radiological protection(3,8).
Considering that ruthenium-106 is a
beta-radiation emitter, it is best indicated in
the treatment of small melanomas, with up
to 6 mm in elevation and a long half-life,
allowing longer periods of use and there-
fore lower cost compared with other iso-
topes. Ruthenium radiation dose calcula-
tion is performed with basis on tables pro-
vided by the manufacturer, and otherwise
expensive computer planning systems are
not necessary(9) (Figure 1).
Main complications associated with
brachytherapy are: retinopathy, cataract,
neovascular glaucoma and maculopathy
which may occur in 9% to 27% of cases in
a three-year period. Main influencing fac-
tors which seem to be related with such
complications are tumor elevation, TMN
stadium, and the proximity of the tumor
with the fovea and optic disc(10).
Most recently, transpupillary thermo-
therapy has started being utilized. It is a
form of therapy utilizing infrared laser di-
ode for inducing hyperthermia with a varia-
tion between 45°C to 60°C. This therapeu-
tic modality is exclusively indicated in
cases of small melanomas in conjunction
with brachytherapy allowing the treatment
of lesions > 5 mm, or even as an adjuvant
therapy in cases where regression is not
achieved or where there is a regression of
the disease(11). Transpupillary thermo-
therapy is characterized by a deep penetra-
tion with an immediate cytotoxic effect, re-
sulting in necrosis of the tumor up to 6 mm
in depth in experiments with animals, and
4.7 mm in melanomas of the choroid in
humans(12).
The ideal therapy for ocular melanomas
still remains controversial, and ocular
brachytherapy and external radiotherapy
with proton beam are adequate therapeutic
options aiming at preserving the ocular
globe and the vision(13,14).
So, the present study is aimed at analyz-
ing the preliminary results from ruthenium-
106 brachytherapy in patients with uveal
melanoma.
MATERIALS AND METHODS
This is a retrospective study performed
on 20 cases of patients with unilateral uveal
melanoma, referred to the Radiotherapy
Unit by the Department of Ophthalmology
of Universidade Federal de São Paulo, for
being submitted to ocular brachytherapy, in
the period between April 2002 and July
2003.
The diagnosis was made by clinical and
ophthalmological examinations. Fluores-
cein angiography and ocular ultrasound A-
and B-scans were requested. Both modes
were employed for evaluating the tumors
elevation. For evaluation of the tumors lo-
calized in the iris and ciliary body ultra-
sonic biomicroscopy was performed.
The staging of patients aiming at char-
acterizing the absence of metastatic lesions
included chest x-ray, abdominal ultra-
sound, hemogram and biochemical analy-
sis. The patients were staged according to
TNM(15) and COMS(16–18) criteria.
For the present study, the following in-
clusion criteria were taken into consider-
ation: diagnosis of unilateral melanoma of
the choroid, iris or ciliary body; tumor ≤ 6
mm in elevation; base diameter ≤ 16 mm;
patients with age ≥ 21 years. Patient’s in-
formed consent. Exclusion criteria were the
following: diagnosis of another malig-
nancy; patients undergoing immunosup-
pressive therapy; patients incapable of re-
turning for follow-up; patients with severe
co-morbidities; multifocal or diffuse le-
sions with scleral infiltration; previously
treated patients; patients with metastasis;
lesions that cannot be delimited by ocular
ultrasound.
Bebig GmbH (Berlin, Germany) ruthe-
nium-106 ophthalmic plaques were uti-
lized. The main feature of these plaques is
beta-radiation emission, with maximum
3.54 MeV energy, and half-life of 365 days.
Two plaque models were employed:
COB (round notched) and CCB (round),
both with 20 mm in diameter (Figure 2). Pa-
tients with lesions proximal to the optic
nerve were submitted to brachytherapy
with the COB plaque, while in the other the
CCB plaque was utilized. Patients with
Figure 1. Calculation of ra-
diation dose, illustrating the
dose rate in mGy/min ×
depth in mm.
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were constructed. The t-test was employed
for evaluating variables related to local
management and visual acuity, and the
paired t-test for comparing pre- and post-
therapy tumor elevation. Contingency
tables were elaborated, and the Fisher’s
exact test was employed for evaluating.
Kaplan-Meier curves were constructed
to estimate survival curves of interest in re-
lation to the progression-free survival.
In all of the tests, the null hypothesis
rejection level was fixed in 0.05 or 5% (p
< 0.05), significant values being marked
with an asterisk, and the non-significant
values, with (NS).
RESULTS
The patients’ ages ranged between 29
and 80 years (median, 56 years). The ma-
jority of patients were Caucasian (95%),
and women (70%) (Table 1).
As regards tumor characteristics, the
right eye was involved in 45%, and the left
eye in 55% of cases. Choroid and/or cili-
ary body melanomas were diagnosed in
85% of patients, and iris melanoma in 15%.
The lesion elevation ranged between 1.14
mm and 6 mm (median, 3.45 mm) (Table
1). TMN staging demonstrated 20% of pa-
Figure 2. RU-106 plaque models: CCB (round) and
COB (round notched).
lesions with more than 5 mm in elevation
(five patients) were submitted to transpu-
pillary thermotherapy delivered to the apex
of the tumor, associated with placement of
the ophthalmic plaque. The prescribed ra-
diation dose was calculated on the apex of
the lesion, from the inner face of the sclera.
The present study covered the follow-
ing aspects: demographic data (age and sex
of patients), tumor characteristics (lesion
site, affected eye, TNM and COMS stag-
ing, tumor elevation), and treatment char-
acteristics (type of plaque, radiation dose
to the apex, base and sclera).
After the treatment, the patients were
clinically evaluated every three months
during the first two years of follow-up, with
the purpose of verifying the local manage-
ment, progression-free survival, the lesion
elevation, rate of preservation of the ocu-
lar globe, visual acuity and presence of
metastases and complications. Ocular ul-
trasound and fluorescein angiography were
performed every three months, and chest x-
ray and abdominal ultrasound, every six
months. The local management was de-
fined as stabilization or decrease in the le-
sion elevation at imaging study in compari-
son with the pre-treatment study. The pres-
ence of lesions in other sites was defined
as metastasis. Progression-free survival
corresponds to absence of local or distance
failure. Treatment-related adverse effects
were considered as complications. The fol-
low-up period started in the date of the
plaque placement.
Parameters regarding demographic, tu-
mor and therapy characteristics, rate of
preservation of the ocular globe, presence
of metastasis and complications were sub-
mitted for a descriptive analysis.
With the purpose of comparing numeri-
cal variables in relation to the local man-
agement, lesion elevation before and after
the therapy, and visual acuity, summary
measures were calculated and box-plots
Table 1 Demographic and evolutive characteristics of patients submitted to ruthenium brachytherapy.
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Age
(years)
46
48
63
62
46
29
46
33
46
64
48
55
57
75
79
80
62
80
54
59
Sex
Male
Female
Female
Female
Male
Female
Female
Female
Male
Female
Female
Male
Female
Male
Female
Female
Female
Male
Female
Female
Eye
Left
Right
Right
Left
Right
Right
Left
Right
Left
Left
Right
Left
Left
Right
Left
Left
Left
Left
Right
Right
Elevation
(mm)
3.35
4.80
1.14
3.50
3.80
1.68
6.00
3.40
3.37
5.50
5.20
3.00
3.41
5.40
3.80
6.00
1.92
2.40
1.57
3.70
Plaque
CCB
COB
CCB
CCB
CCB
CCB
CCB
COB
COB
CCB
CCB
COB
CCB
CCB
CCB
COB
CCB
CCB
CCB
CCB
Time
(days)
2
3
2
3
3
2
4
2
2
5
4
3
4
5
4
4
2
3
3
5
Apex dose
(cGy)
9.475
7.379
10.488
9.072
8.986
9.532
5.932
8.064
7.891
8.280
8.502
8.493
8.582
6.278
7.142
5.587
8.493
8.680
8.432
8.160
Final elevation
(mm)
0.68
0.00
0.89
3.30
3.10
1.60
1.80
0.00
0.00
4.00
3.90
3.00
2.54
4.60
2.90
6.30
1.36
2.60
1.50
3.50
Complication
No
Visual worsening
No
No
No
No
No
Visual worsening
Visual worsening
No
No
No
No
Infectious
No
No
No
Visual worsening
No
No
CCB, round plaque; COB, round notched plaque.
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tients staged as T1, and 80% as T2. Accord-
ing to COMS criteria, 10% of lesions were
small-sized, and the remaining 90%, inter-
mediate. As regards the therapy, the radia-
tion dose to the apex ranged between 55.8
Gy and 104.8 Gy (median, 84.6 Gy). The
median of the radiation-dose to the tumor
base and sclera was respectively 248.3 Gy
and 319.4 Gy. The CCB plaque was uti-
lized in 75% of cases. The follow-up pe-
riod ranged between 9 and 23 months (me-
dian, 19 months).
During the clinical follow-up, an in-
crease in the tumor dimensions was ob-
served in five cases (25%). Of these pa-
tients, three were submitted to adjuvant
transpupillary thermotherapy, and currently
are under follow-up, with no evidence of
disease progression. Two patients could not
undergo transpupillary thermotherapy be-
cause of the lesion localization. One of
them is under observation, and enucleation
is schedule for the other. Table 2 shows the
local management with brachytherapy and
associated with transpupillary thermo-
therapy. The initial elevation of the lesion
(p  = 0.883), the prescribed radiation-dose
to the tumor apex (p = 0.879) and the le-
sion localization (p = 1.000) did not con-
stitute significant factors for the local man-
agement of the disease. The progression-
free survival with brachytherapy and with
adjuvant transpupillary thermotherapy may
be observed in Kaplan-Meier survival
curves (Figure 3). One patient progressed
to death nine months after therapy due to
unrelated causes. Comparing the initial el-
evation of the lesion with the elevation af-
ter the therapy, a significant reduction (p =
0.001) was observed (Figure 4). No patient
was submitted to enucleation. As regards
visual acuity at the moment of the latest
evaluation, 70% of patients presented a vi-
sual acuity higher than 20/200, and 30%
presented visual acuity equivalent or lower
than 20/200. The prescribed radiation dose
to the tumor base and sclera did not con-
stitute a prognosis factor of significance for
the visual acuity.
During the follow-up period distant
metastases were not detected. Complica-
tions were observed in 25% of cases. In
four patients, visual acuity worsening was
observed in one patient, and another pre-
sented infectious complication.
DISCUSSION
Results regarding demographic com-
pare favorably with previous studies pub-
lished in the literature, demonstrating a
predominance of uveal melanoma in Cau-
casian patients with median age of 60
years. Singh and Tophan, in an epidemio-
logical analysis of melanomas in the United
States reported a 97.8% incidence in Cau-
casian individuals. In this same study, the
ages of the population studied ranged be-
tween 6 and 100 years, 59.4 year for men,
and 61.5 for women (median, 59.4 years).
As regards sex, uveal melanoma seems to
present a slightly high incidence in men.
Notwithstanding this fact has not been ob-
served in the present study, this may be jus-
tified by the low number of patients in com-
parison with studies performed for inci-
dence evaluation(1).
In the analysis of the tumor character-
istics, melanomas most frequently were
located in the choroid. Also, a higher num-
ber of cases of iris melanomas were ob-
served in the present study in relation to the
literature where the reported incidence
achieves only 2%–3% for lesions localized
in this topography(19). The mild predomi-
nance in the left eye observed in the present
Table 2 Local management after brachytherapy and brachytherapy with transpupillary thermotherapy.
Treatament
Brachytherapy
Brachytherapy + TTT
 N
15
18
Rate
75%
90%
N
5
2
Rate
25%
10%
 N
20
20
Rate
100%
100%
Local management Failure Total
TTT, transpupillary thermotherapy.
Figure 4. Initial tumor elevation in relation to the final elevation.
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Figure 3. Kaplan-Meier estimation of progression-free survival in patients
submitted to ruthenium-106 brachytherapy and adjuvant transpupillary ther-
motherapy.
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study also is reported by some studies in the
literature. Hermann et al. observed that in
56% of cases, the tumors were localized in
the left eye(20). However, this difference
was not observed in studies involving a
higher number of cases(18).
All of the lesions were staged as T1 or
T2N0M0 by the TNM (6th edition)(15), and
as intermediate by the COMS. In other
publications about the employment of ru-
thenium-106 in melanomas therapy, a pre-
dominance of tumors staged as T1 and T2
also is observed. This is due the fact that
ruthenium-106 is a Beta-radiation emitter
with low penetrability, besides not being
indicated for more extensive lesions. Also,
it may be added that the majority of stud-
ies was based on the staging method rec-
ommended by the International Union
Against Cancer (UICC) in 1997(21), classi-
fying choroid melanomas with > 5 mm in
elevation and/or >15 mm in diameter as T3.
According to the TMN 6th edition, only
those lesions with > 16 mm in its larger
diameter and/or > 10 mm in elevation
would be classified as T3. So, considering
the new staging, one can say that the inci-
dence of T1 and T2 tumors described in the
literature probably is higher. This also can
be confirmed by the comparison between
the median elevation of the lesions in the
present study (3.45 mm) and that reported
in the literature, ranging from 3 mm to 5.2
mm(22,23).
The most utilized plaque was the round-
shaped CCB. The greatest majority of stud-
ies performed with ruthenium-106 plaques
do not describe the plaque models. In the
present study, the CCB model was utilized
in the treatment of patients with central
lesions, proximal to the optic nerve, while
the COB plaque was utilized in the remain-
ing. As regards the lesions localization, the
literature reports a lower incidence of cen-
tral lesions in comparison with paracentral,
peripheral or yet ciliary body and iris le-
sions. In the study performed by the
COMS, lesions at 0–2 mm from the optic
disc corresponded to only 14.9% of
cases(24). On the other hand, in other pub-
lications, central lesions were observed in
35% of cases, these results being similar to
the ones from the present analysis(17).
The ruthenium-106 plaque time of per-
manence ranged between two and five days
(median, three days), and was directly pro-
portional to the prescribed radiation-dose
delivered to the tumor apex, and inversely
proportional to the plaque activity. The
prescribed dose delivered to the tumor apex
ranged between 55 Gy and 105 Gy (me-
dian, 85 Gy), and to the base, the prescribed
dose ranged between 148 Gy and 450 Gy.
The dose delivered to the sclera ranged
between 191 Gy and 578 Gy. The radiation
dose to be prescribed to the tumor apex
with ruthenium-106 is still to be defined in
the literature. In an analysis of several stud-
ies in the literature about the use of ruthe-
nium plaque for treatment of melanomas,
one can observe that most of times the dose
ranges between 80 Gy and 100 Gy, but
studies with doses from 60 Gy to 160 Gy
may be found. Rouberol et al. have treated
213 patients affected by choroid and cili-
ary body melanoma with a 60 Gy dose(25).
Shields et al., in a study about visual acu-
ity in 1,106 patients with uveal melanoma
submitted to brachytherapy with iodine-
125, ruthenium-106, cobalt-60 or iridium
-192, have described a median dose of 90.9
Gy to the apex, and 330 Gy to the tumor
base(26). Seregard, in a meta-analysis with
1,066 patients treated with ruthenium-106
has observed a dose to the apex ranging
between 80 Gy and 100 Gy(27). A study
describing the Dutch experiment with ru-
thenium for uveal melanoma utilized doses
up to 160 Gy delivered to the tumor apex,
and doses to the sclera from 220 Gy to 950
Gy(3). Hermann et al., analyzing the effect
of the dose-assignment in relation to results
from ruthenium-106 plaque brachytherapy,
utilized doses of 120 Gy to the apex of the
tumor(20). Shields et al., in a study with con-
comitant transpupillary thermotherapy and
brachytherapy, describe a dose to the apex
ranging between 55 Gy and 124 Gy (me-
dian, 90 Gy), and 254 Gy to the base(11). As
regards radiation dose to be utilized, the
American Brachytherapy Society recom-
mends the dose of 85 Gy to the apex of the
lesion when iodine-125 is utilized as radio-
isotope(14). However, these same guidelines
recommend a dose from 120 Gy to 160 Gy
aiming at maximizing the healing effect
when rutheium-106 is utilized. Meanwhile,
the American Brachytherapy Society sug-
gests that this large dose gradient may re-
sult in high doses to the sclera, which may
cause a higher number of complications(14).
In a randomized prospective study devel-
oped by the COMS utilizing iodine-125 in
the treatment of choroid melanomas, in
49.9% of cases, the dose to the apex was
85.1 Gy to 120 Gy, and in 41.3% of patients
the dose to the sclera ranged between 293
Gy and 409.9 Gy(27). So, studies evaluating
dose-assignment excepted, the doses uti-
lized in the present study are compatible
with data in the literature regarding pre-
scribed radiation dose to the apex of the
lesion, to the tumor base and sclera.
Our results in relation to local manage-
ment and progression-free survival com-
pare to previous studies, despite the diffi-
culty to evaluate retrospective data from
different centers, considering variations in
follow-up periods, tumors dimensions and
doses delivered. Summanen et al., evaluat-
ing 100 patients treated with ruthenium-
106, have observed local failure in 19% of
cases with 0.1 to 2.7 years of follow-up
(median, 0.7 year)(28). This leads to the con-
clusion that local failures occur preco-
ciously, especially in the first years of fol-
low-up, and are very significant for the
interpretation of our results. Studies with
similar follow-up periods demonstrate a
complete tumor regression in 57.1% of
cases and local recidivation in 31% of pa-
tients(29). Foerster et al., evaluating the ru-
thenium therapy in100 patients affected by
uveal melanoma, have observed local re-
cidivation of 12%, with a median two-year
follow-up period(30). Seregard, in a review
of the Swedish experiment with transpu-
pillary thermotherapy as an adjunct to ru-
thenium brachytherapy, has observed in a
20-month follow-up period that in 70.3%
of cases there was a partial or complete
regression of the lesion, a result very simi-
lar to the 75% local management observed
in the present study(31).
Lommatzsch et al., analyzing 141 pa-
tients submitted to ruthenium brachyther-
apy at a dose of 100 Gy, have observed a
disease-free survival rate corresponding to
89.6% in five years(32). Seregard, in a meta-
analysis involving 1,066 patients treated
with ruthenium at doses between 80 Gy and
100 Gy, has observed a disease-free sur-
vival of 86% in five years(27). In the present
study, once the progression-free survival of
patients submitted to brachytherapy and
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transpupillary thermotherapy is analyzed,
one may observe that our results are simi-
lar to those in the literature, with a longer
follow-up period and higher number of
cases.
Studies evaluating the dose-assignment
effect on the local management show con-
troversial results. Tjho-Heslinga et al., uti-
lizing a dose to apex of 160 Gy in 101 pa-
tients affected by uveal melanoma, have
observed complete and partial remission in
respectively 62.6% and 31.3% of cases,
these results being slightly superior to those
described in the literature with the usual
doses. In the present study, transpupillary
thermotherapy also was utilized in 25 pa-
tients, allowing a reduction in the radiation
dose and, consequently, in the risk of ret-
inopathy(3). However, in another study with
a 120 Gy dose to the apex of the lesion in
patients with choroid melanomas, the ben-
efit from the dose-assignment to the sur-
vival has not been observed(20).
In a literature review, elevation and
larger basal diameter of the tumor, dose de-
livered to the tumor apex and retinal de-
tachment play a significant role in relation
to the local management and disease-free
survival(27). In the present study, factors like
lesion elevation, radiation dose, and tumor
localization did not affect the local man-
agement of the disease. This may have oc-
curred because of the number o patients
and number of failures observed, since this
is a rare malignant neoplasm. Also, it may
be added that the concomitant employment
of transpupillary thermotherapy and
brachytherapy in patients with lesions > 5
mm may have contributed to the favorable
and similar results of patients with larger
lesions who received lower radiation dose
to the apex of their tumors.
The post-therapy tumor elevation was
significantly lower than that before the
treatment, evidencing that the therapy was
effective, allowing a decrease in the tumor
thickness of about 65% of the initial eleva-
tion. In a literature review in terms of re-
duction of tumor elevation after ruthenium
brachytherapy, a reduction around 3%/
month is observed, and the majority of le-
sions do not present a complete regression,
stabilizing at a constant value around 61%
of the initial elevation after approximately
24 months(23). In our series, results concern-
ing enucleation and visual acuity are
slightly better than those in the literature. .
Quivey et al. have observed that 58% of
239 patients treated with iodine plaques
maintained a vision ≥ 20/200(33). The
COMS Report no. 16 has evaluated the
visual acuity of patients three years after
iodine brachytherapy and observed an
enucleation rate of 6.2% and visual acuity
≤ 20/200 in 43% of cases.  In this same
study, after a 24-month follow-up, com-
pared with our series, 4% of the patients
had been enucleated, and 33% presented
visual acuity ≤ 20/200(24). In another analy-
sis of visual acuity after brachytherapy,
Shields et al. have observed that in 51% of
cases the visual acuity was ≤ 20/200(26).
Notwithstanding our results have shown
that the prescribed radiation dose does not
affect the visual acuity, probably because
of the number of cases, the factors that
seem to be related to the visual acuity after
the therapy are: the isotope utilized, the
presence of diabetes, the tumor elevation,
the lesion localization, the type of plaque
utilized, and the presence of retinal detach-
ment(24).
The presence of metastasis is observed
in about 10%-20% of patients with uveal
melanoma, and is related mainly to the tu-
mor size(34). In our series, the presence of
metastasis was not observed. This may be
explained by the fact that the present study
includes only patients at the initial phase of
the disease, with tumors ≤ 6 mm in eleva-
tion.
Analyzing this series as a whole, despite
the short follow-up period and the small
number of patients, our results show that
ruthenium brachytherapy allowed a good
local management of the disease and a rea-
sonable progression-free survival in the
studied population. Notwithstanding enu-
cleation would be the therapy indicated in
our institution, the use of this radioisotope
allowed, in all of the cases, the preserva-
tion of the ocular globe, and the mainte-
nance of the visual acuity at a certain ex-
tent.
This is the first study about the use of
ruthenium in our country, and we consider
that this radioisotope may be exclusively
utilized in the treatment of uveal melano-
mas with up to 5 mm in elevation, while
patients with lesion with more than 6 mm
in elevation are candidates to brachyther-
apy with other radioisotopes. In cases of
melanomas with 5 mm to 6 mm in eleva-
tion, ruthenium brachytherapy must, if
possible, be associated with transpupillary
thermotherapy.
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